<?xml version='1.0' encoding='utf-8'?>
<document id="27608830"><sentence text="Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population - an analysis based on German insurance claims data." /><sentence text="Numerous drugs used in the treatment of psychiatric disorders are substrates of cytochrome P450 enzymes and are potential candidates for drug-drug interactions (DDIs)" /><sentence text="" /><sentence text="Claims data of a German statutory health insurance company from severely mentally ill patients who registered in an integrated care contract from August 2004 to December 2009 were analysed" /><sentence text=" We measured time periods of concomitant prescription of drugs that have been reported to interact via cytochrome P450, with a focus on drugs acting as strong inhibitors" /><sentence text=" Such drug-drug exposure (DDE) is an incontrovertible precursor of DDIs" /><sentence text=" We assessed whether potential DDIs were considered clinically relevant based on the prescribing information of the respective drugs" /><sentence text="" /><sentence text="Among all 1221 patients, 186 patients (15" /><sentence text="2 %; Clopper-Pearson 95 % confidence interval (CI): 13" /><sentence text="3-17" /><sentence text="4 %) had at least one DDE prescription, and 58 patients (4" /><sentence text="8 %; 95 % CI 3" /><sentence text="6-6" /><sentence text="1) had at least one DDE prescription involving a strong cytochrome P450 inhibitor" /><sentence text=" In 59 patients, (4" /><sentence text="8 %; 95 % CI: 3" /><sentence text="7-6" /><sentence text="2 %) five or more DDEs were identified, and five or more DDEs with a strong inhibitor were identified in 18 patients (1" /><sentence text="5 %; 95 % CI: 0" /><sentence text="9-2" /><sentence text="3)" /><sentence text=" The rates of DDEs were 0" /><sentence text="27 (Garwood 95%CI: 0" /><sentence text="25-0" /><sentence text="28) per person-year and 0" /><sentence text="07 (95 % CI: 0" /><sentence text="07-0" /><sentence text="08) for strong-inhibitor DDEs" /><sentence text=" Four of the ten most frequent DDEs were identified as clinically relevant, and seven of the eight most frequent DDEs involving a strong inhibitor were clinically relevant" /><sentence text="" /><sentence text="The number of patients with DDEs was not alarmingly high in our sample" /><sentence text=" Nevertheless, prescription information showed that some prescribed drug combinations could result in serious adverse consequences that are known to weaken or strengthen the effect of the drugs and should therefore be avoided" /><sentence text="" /></document>